Sanofi spent $300 million in cash to get into a $1.7 billion alliance with Lexicon on their SGLT1/2 diabetes drug sotagliflozin. And now that the drug has been spurned by the FDA after burning through a program that provided mixed late-stage data and a late shot at a last-place finish, the French pharma giant is forking over another $260 million to get out of the deal.
The European Medicines Agency (EMA) announced Friday that its Committee for Medicinal Products for Human Use (CHMP) recommended six medicines and nine indication extensions for approval, including for the first oral add-on treatment for type 1 diabetes, and issued its opinion on the sartan safety issues.
Sun Pharmaceutical`s Bortezomib SUN (bortezomib) receive market authorisation in EU for Multiple Myeloma